

## DRUG-RESISTANT TUBERCULOSIS CLINICAL TRIALS PROGRESS REPORT

Trial Name	Description	Status	Phase	Trial Registry Identifier (link)	Expected Study Completion Date
Janssen C211	Evaluate the PK, safety, tolerability and anti-mycobacterial activity of bedaquiline in combination with MDR-TB therapy for HIV uninfected children and adolescents	Currently enrolling in Philippines, Russian Federation, and South Africa	Phase 2	<a href="#">NCT02354014</a>	2025
STREAM Stage 2	Comparison of 6 and 9 month bedaquiline-containing regimen against the WHO and Bangladesh regimen	Open for participant enrollment	Phase 3	<a href="#">NCT02409290</a>	2021
NeXT	Open label RCT of a 6-9 month injection free regimen containing bedaquiline, linezolid, levofloxacin, ethionamide/high dose isoniazid, and pyrazinamide	Enrollment suspended	Phase 3	<a href="#">NCT02454205</a> <a href="#">PACTR201409000848428</a>	2019
NiX-TB	Study of bedaquiline, pretomanid, and linezolid in patients with XDR-TB and MDR-TB for 6 months with an option of 9 months	Completed; <a href="#">results</a>	Phase 3	<a href="#">NCT02333799</a>	Completed
DELIBERATE (ACTG 5343)	Study of drug-drug interactions and combined QT effects of bedaquiline and delamanid	<a href="#">Fully enrolled</a> Preliminary results	Phase 2	<a href="#">NCT02583048</a>	2020
Otsuka 233	Safety, efficacy, and pharmacokinetic study of delamanid in pediatric patients with MDR-TB	Fully enrolled.	Phase 2	<a href="#">NCT01859923</a>	2020
Otsuka 232	Pharmacokinetic and safety trial of delamanid to determine the appropriate dose for pediatric MDR-TB HIV- patients	Completed; results pending	Phase 1	<a href="#">NCT01856634</a>	2019
ACTG 5312	Safety and efficacy study of different doses and generic variants of isoniazid resistant TB	Stage 1 preliminary results; <a href="#">Stage 2 underway</a>	Phase 2	<a href="#">NCT01936831</a>	2020
Opti-Q	Efficacy and safety study of increased doses of levofloxacin in combination with optimized background therapy	Follow up completed; analysis underway	Phase 2	<a href="#">NCT01918397</a>	2020

## DRUG-RESISTANT TUBERCULOSIS CLINICAL TRIALS PROGRESS REPORT

Trial Name	Description	Status	Phase	Trial Registry Identifier (link)	Expected Study Completion Date
V-QUIN	Evaluating 6 months daily levofloxacin vs. placebo as preventive therapy in contacts of MDR-TB. Enrolling Children, adolescents, infants HIV+/HIV- Household randomization	Currently enrolling participants in Vietnam	Phase 3	<a href="#">ACTRN12616000215426</a>	2019
MDR-END	Comparing efficacy of treatment regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for 9-12 months, with a control arm of the standard treatment regimen including injectables for 20-24 months for the treatment of quinolone sensitive MDR-TB	Currently enrolling participants in South Korea	Phase 2	<a href="#">NCT02619994</a>	2021
TB-CHAMP	Randomized double blind placebo-controlled, superiority multicenter trial to evaluate the efficacy of levofloxacin vs. placebo for the prevention of MDR-TB in child and adolescent household contacts	Currently enrolling participants in South Africa	Phase 3	<a href="#">ISRCTN92634082</a>	2020
Janssen Japan Trial	Open-label, single-arm, multi-center trial to explore safety, efficacy and PK of bedaquiline in Japanese participants with pulmonary MDR-TB	<a href="#">Completed Preliminary Results</a>	Phase 2	<a href="#">NCT02365623</a>	Completed
endTB	Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of new combination regimens for FQ-susceptible MDR-TB treatment	Currently enrolling participants in Georgia, Peru, Kazakhstan, and Lesotho	Phase 3	<a href="#">NCT02754765</a>	2022
TB-PRACTECAL	Multi-centre, open label, multi-arm, randomized, controlled, phase II-III trial evaluating short treatment regimens containing bedaquiline and pretomanid in combination with existing and re-purposed anti-TB drugs for the treatment of biologically confirmed pulmonary MDR-TB	Currently enrolling participants in Uzbekistan, South Africa, and Belarus	Phase 2-3	<a href="#">NCT02589782</a>	2022
ZeNix	Evaluate the efficacy, safety and tolerability of various doses and durations of linezolid plus bedaquiline and pretomanid after 26 weeks of treatment in participants with either pulmonary XDR-TB, pre-XDR-TB, or treatment intolerant or non-responsive MDR-TB.	Currently enrolling participants in Georgia, Republic of Moldova, Russian Federation, South Africa	Phase 3	<a href="#">NCT03086486</a>	2020

## DRUG-RESISTANT TUBERCULOSIS CLINICAL TRIALS PROGRESS REPORT

Trial Name	Description	Status	Phase	Trial Registry Identifier (link)	Expected Study Completion Date
SimpliciTB	DR-TB pateints given BPamZ for 26 weeks (or 6 months).	Currently enrolling patients	Phase 2-3	<a href="#">NCT03338621</a>	2022
IMPAACT 2005 (DAIDS ID 20721)	The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of Delamanid in combination with optimized multidrug background regimen (OBR) for multidrug-resistant tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected children with MDR-TB	Currently enrolling participants in Botswana, India, South Africa and Tanzania	Phase 1-2	<a href="#">NCT03338621</a>	2021
IMPAACT 2005 (DAIDS ID 11884)	The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of an antituberculosis drug, bedaquiline (BDQ), when used to treat multidrug-resistant tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected infants, children, and adolescents.	Currently enrolling non-US participants in Haiti, India and South Africa	Phase 1-2	<a href="#">NCT03141060</a>	2022
BEAT-Tuberculosis	Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care	Currently open for enrollment in South Africa	Phase 3	<a href="#">NCT04062201</a>	2023
ACTG A5300/IMPAACT P2003B (PHOENix)	The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB) (index cases). High-risk HHCs are those with HIV or non-HIV immunosuppression, latent TB infection, and young children below the age of 5 years.	Enrolling; high-risk infant, child, adolescent, and adult household contacts of individuals with MDR-TB	Phase 3	<a href="#">NCT03568383</a>	2025
BEAT-TB (India)	Evaluation of the Efficacy and Safety of a Combination regimen of Bedaquiline, Delamanid, Linezolid and Clofazimine in Adults with Pre-extensive (Pre-XDR) and Extensively Drug-resistant Pulmonary Tuberculosis (XDR-TB):Prospective Cohort Study	Currently open for enrollment in India	N/A	<a href="#">CTRI/2019/01/017310</a>	2023